Ocular Toxicity of Nanoparticles - Biointeractions of Nanomaterials - page 352

is their advanced drug load that they can carry [2]. However, due to the nature of its synthesis, a
potential source of toxicity may be the presence of excipients on the nanoparticle [2]. In addition,
some surfactants dissociate from the nanoparticle during sterilization due to the high temperatures,
another potential source of toxicity; there is no dissociation of surfactants at body temperature [2].
REFERENCES
1. Vadlapudi AD, Mitra AK. Nanomicelles: An emerging platform for drug delivery to the eye. Therapeutic
Delivery . 2013;4(1):1-3.
2. Prow TW. Toxicity of nanomaterials to the eye. Wiley Interdisciplinary Reviews: Nanomedicine and
Nanobiotechnology . 2010;2(4):317-33.
3. Christoforidis JB, Chang S, Jiang A, Wang J, Cebulla CM. Intravitreal devices for the treatment of vitre-
ous inflammation. Mediators of Inflammation. . 2012.
4. Raju HB, Hu Y, Vedula A, Dubovy SR, Goldberg JL. Evaluation of magnetic micro- and nanoparticle
toxicity to ocular tissues. PLoS One . 2011;6(5):e17452.
5. Prow TW, Bhutto I, Kim SY, Grebe R, Merges C, McLeod DS et al. Ocular nanoparticle toxicity and
transfection of the retina and retinal pigment epithelium. Nanomedicine: Nanotechnology, Biology and
Medicine . 2008;4(4):340-9.
6. Wong LL, Hirst SM, Pye QN, Reilly CM, Seal S, McGinnis JF. Catalytic nanoceria are preferentially
retained in the rat retina and are not cytotoxic after intravitreal injection. PLoS One . 2013;8(3):e58431.
7. Jessica E. Nanoceria exhibit redox state-dependent catalase mimetic activity. Chemical Communications .
2010;46(16):2736-8.
8. Self WT, Seal S. Nanoparticles of cerium oxide having superoxide dismutase activity. Google Patents;
2009.
9. Asati A, Santra S, Kaittanis C, Perez JM. Surface-charge-dependent cell localization and cytotoxicity of
cerium oxide nanoparticles. ACS Nano . 2010;4(9):5321-31.
10. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small . 2010;6(1):12-21.
11. Han Z, Conley SM, Makkia R, Guo J, Cooper MJ, Naash MI. Comparative analysis of DNA nanopar-
ticles and AAVs for ocular gene delivery. PLoS One . 2012;7(12):e52189.
12. Amado D, Mingozzi F, Hui D, Bennicelli JL, Wei Z, Chen Y et al. Safety and efficacy of subretinal
readministration of a viral vector in large animals to treat congenital blindness. Science Translational
Medicine . 2010;2(21):21ra16.
13. Ding X-Q, Quiambao AB, Fitzgerald JB, Cooper MJ, Conley SM, Naash MI. Ocular delivery of com-
pacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS One . 2009;4(10):e7410.
14. Liu G, Li D, Pasumarthy MK, Kowalczyk TH, Gedeon CR, Hyatt SL et al. Nanoparticles of compacted
DNA transfect postmitotic cells. Journal of Biological Chemistry . 2003;278(35):32578-86.
15. Fink T, Klepcyk P, Oette S, Gedeon C, Hyatt S, Kowalczyk T et al. Plasmid size up to 20 kbp does
not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Therapy .
2006;13(13):1048-51.
16. Cai X, Conley SM, Nash Z, Fliesler SJ, Cooper MJ, Naash MI. Gene delivery to mitotic and postmitotic
photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of
retinitis pigmentosa. The FASEB Journal . 2010;24(4):1178-91.
17. Declercq SS, Meredith P, Rosenthal AR. Experimental siderosis in the rabbit: Correlation between elec-
troretinography and histopathology. Archives of Ophthalmology . 1977;95(6):1051-8.
18. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanopar-
ticles, nanocapsules, and nanoemulsions, as ocular drug carriers. Journal of Pharmaceutical Sciences .
1996;85(5):530-6.
19. Pitt C. Poly- e -caprolactone and its copolymers. In: Chasin M, Langer R, eds. Biodegradable Polymers as
Drug Delivery Systems . New York, NY: Marcel Dekker; 1990. p. 71.
20. Silva-Cunha A, Fialho SL, Naud MC, Behar-Cohen F. Poly- e -caprolactone intravitreous devices: An in
vivo study. Investigative Ophthalmology Visual Science . 2009;50(5):2312-8.
21. Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: Strategies and underly-
ing principles. Nanomedicine . 2010;5(3):485-505.